



PRESS RELEASE

12 July 2024 13:55:00 CEST

AcouSort and GenSensor collaboration develops according to plan

In April 2024, AcouSort AB (“AcouSort”) and GenSensor SAS (“GenSensor”) announced that the two companies will collaborate to combine AcouSort’s acoustofluidics technology with GenSensor’s Biology First Process Analytical Technology to accelerate bioprocess design and improve monitoring systems for bioreactor culturing. GenSensor has now placed its first order for AcouTrap modules to be used for internal product development.

By combining the two companies’ technologies, AcouSort and GenSensor aim to automate cell capture and clean-up prior to molecular analysis. Initially, the collaboration focuses on integration of AcouTrap units with GenSensor’s device as well as development of a new generation of devices dedicated to bioprocess monitoring and additional data collection regarding the isolated samples. In a future commercial phase, AcouSort will provide its AcouTrap units to GenSensor as OEM components.

“I am very pleased that the collaboration with GenSensor develops according to plan. AcouSort and GenSensor share a common interest in providing the healthcare market with innovative solutions that leads to better patient outcomes upon treatment,” says Agnes Michanek, Commercial Director at AcouSort.

ABOUT GENSENSOR

GenSensor was founded with a vision to become a game changer in the field of *biology first Process Analytical Technology*. The company develops robotic devices and AI algorithms to monitor, characterize and optimize bioproduction of ATMP and vaccines.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).